Gastrointestinal hormones, including glucagon-like peptide-1 (GLP-1), are currently used for the treatment of metabolic diseases and endogenous GLP-1 contributes to the glucose lowering and weight reducing effect of Roux-en-Y gastric bypass (RYGB) [11, 12]. Here, GLP1R is linked to metabolic disease.